Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parasitic β-tubulin is a core component of microtubules in protozoan and helminth parasites, structurally similar to β-tubulin in other eukaryotes. Together with α-tubulin, it forms obligate α/β heterodimers, which polymerize to build dynamic microtubules essential for mitosis, morphology, intracellular transport, motility, and cell division[3][4][6]. β-Tubulin's essentiality makes it a validated target for antiparasitic drugs, especially benzimidazoles, which selectively disrupt parasite microtubules by binding to β-tubulin and inhibiting polymerization, leading to cytoskeletal collapse and parasite death[6][4]. β-Tubulin can elicit protective immune responses and serve as a biomarker for infection[4]. Drug efficacy and toxicity are influenced by the high degree of evolutionary conservation between parasitic and host β-tubulin, underlying challenges of drug selectivity and resistance mutations[6][4].
Drugs such as benzimidazoles bind to β-tubulin, inhibiting microtubule polymerization, disrupting cytoskeleton assembly, and blocking cell division in parasites[6][4].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-tubulin (parasitic) (β-tubulin).